Prevention, Diagnosis & Treatment
Bayer’s brands treat and prevent conditions to improve quality of life.
April 11, 2019
Bayer Announces Results of Sub-group Analysis for Vitrakvi® (larotrectinib) in Patients with NTRK Gene Fusion-Positive Metastatic Non-small Cell Lung Cancer (NSCLC)
Bayer today presented subgroup analysis data of patients with non-small cell lung cancer with neurotrophic receptor tyrosine kinase (NTRK) gene fusion treated with Vitrakvi® (larotrectinib).1...
March 27, 2019
Bayer Data at AACR 2019 Underscores Company's Commitment to Advancing the Future of Cancer Care
Bayer will present research from its growing oncology portfolio at the American Association for Cancer Research (AACR) 2019 Annual Meeting, taking place March 29 to April 3 in Atlanta. The...
February 15, 2019
Bayer to obtain full rights to global development and commercialization of oncology compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and...
Last Updated: September 19, 2018